Gooch & Housego (GHH) H1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2025 earnings summary
11 Mar, 2026Executive summary
Revenue increased 11.4% year-over-year to £70.9m, with adjusted operating profit up 60.5% to £6.2m, driven by strong Aerospace & Defence and Life Sciences growth, despite Industrial decline and macroeconomic challenges.
Strategic progress included successful integration of Phoenix Optical and acquisition of Global Photonics, expanding US and defense capabilities.
Order book rose to £121.5m, providing over 95% cover for FY2025 revenues.
Margin improvement achieved through outsourcing, productivity gains, and portfolio enhancement.
Interim dividend maintained at 4.9p per share.
Financial highlights
Organic constant currency revenue growth of 7.5%, with gross margin improving to 30.4% from 29.1%.
Adjusted profit before tax reached £5.1m; adjusted basic EPS was 15.0p.
Net cash from operations was £2.6m; net debt increased to £35.5m (leverage ratio 1.3x).
Capital expenditure focused on fibre optic and crystal growth capacity.
Non-underlying charges of £2.2m, mainly from M&A and restructuring.
Outlook and guidance
Full-year performance expectations unchanged, with over 95% order book cover for FY2025 revenues.
Near-term execution risks elevated due to macroeconomic and geopolitical uncertainty, especially from new US tariffs and Chinese retaliatory measures.
Confident in delivering mid-teen returns by 2028, supported by structural growth drivers and operational improvements.
Capital expenditure guidance for FY25 is £7–8m; R&D spend expected at £7m (5% of revenue).
Adjusted effective tax rate forecasted at 23–24%.
Latest events from Gooch & Housego
- Revenue up, profit down; strong order book and A&D/Life Sciences offset industrial weakness.GHH
H2 202411 Mar 2026 - Revenue and profit fell, but improved margins and a strong order book support a positive outlook.GHH
H1 202411 Mar 2026 - Acquisition creates a U.S. optical systems hub, boosting defense capabilities and growth potential.GHH
M&A announcement11 Mar 2026 - Double-digit revenue and profit growth driven by A&D and acquisitions, with a record order book.GHH
H2 202511 Mar 2026 - Solid FY2024 results and acquisitions set the stage for growth in Life Sciences and Defence.GHH
Investor presentation11 Mar 2026 - Order book grew to £126.4M, driven by innovation, acquisitions, and operational improvements.GHH
AGM 2025 presentation11 Mar 2026 - Double-digit revenue growth and record order intake driven by A&D and new technology focus.GHH
AGM 2026 presentation11 Mar 2026 - Revenue delays impact FY2024, but strategic progress and FY2025 outlook remain strong.GHH
Trading update11 Mar 2026 - Strong second half trading and robust cash generation position the group for next year's recovery.GHH
Trading update11 Mar 2026